COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 1 of 48 Hawaii
Biotechnology Research: Interest Areas and Opportunities with the
Department of Defense COL Karl Friedl, PhD Telemedicine &
Advanced Technology Research Center US Army Medical Research &
Materiel Command Frederick, MD Slide 2 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
2 of 48 A hiatus exists between the inventor who knows what they
could invent, if they only knew what was wanted, and the soldiers
who know, or ought to know, what they want and would ask for it if
they only knew how much science could do for them. - Winston S.
Churchill (1929) Slide 3 COL Karl Friedl/MCMR-TT (301-619-7967)
(DSN 343) [email protected] UNCLASSIFIED Slide 3 of 48 Agenda
Military medical research interests Military medical research
interests Biomedical research in the DoD Biomedical research in the
DoD USAMRMC organizational structure USAMRMC organizational
structure Competitive funding opportunities Competitive funding
opportunities Hawaii Federal Healthcare Network Program Hawaii
Federal Healthcare Network Program Slide 4 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
4 of 48 S&T Shortfalls Capability Today Existing Tech or
Non-Technology Solutions Ongoing S&T Work Needed S&T Work
Desired Capabilities Current Operational Concepts and Environment
Future Operational Concepts and Environment Capability Challenges
Capability Needs Technology Shortfalls: Fill the Gaps Slide 5 COL
Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 5 of 48 Procurement $
6.3 Ops & Maint $ 6.4 6.16.26.5 6.7 Research, Development,
Test, & Evaluation (RDT&E) $ Life Cycle A Program
Management Initiation BC MDD ICDCDDICDCPD Fed / DoD Needs
Opportunities, Gaps, & Resources DoD Funding Categories 6.1
6.3: Basic research, applied research, and advanced technology
development 6.4 6.5: Program management activities 6.6: Program
support including test and evaluation facilities 6.7: Improvements
to existing operational systems Joint Capability Integration &
Development System Documents ICD: Integrated Capabilities Documents
CDD: Capability Development Documents CPD: Capability Production
Documents Funding The Linear Approach to R&D Army Medical
Product Development Life Cycle Vannevar Bush model Basic research
is a pacemaker of technological innovation but must be segregated
to avoid premature thoughts of practical use Slide 6 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 6 of 48 Understanding underlying science creates
rule base to help solve future problems Low Emphasis on Fundamental
Understanding High Emphasis on Basic Science Low Emphasis on
Applications Pure basic research (Bohr) High Emphasis on
Applications Pure applied research (Edison) Use-inspired basic
research (Pasteur) DoD Problem-solving Focus: Use-inspired Medical
Research Revolutionary Evolutionary Slide 7 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
7 of 48 What are the DoD Medical Research Priorities? (Where do
they come from?) National strategic plans (e.g., Quadrennial Review
in progress!) Secretary of Defense & other authoritative
sources in the DoD and Services Armed Services Biomedical Research
Evaluation and Management Near-term problems identified by field
commanders & COCOMs Slide 8 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
8 of 48 Secretary Gates' Press Briefing May 3, 2007 Apart from the
war, this department and I have no higher priority than to ensure
wounded servicemembers have the best care and facilities and ample
assistance navigating the next step in their lives. That is what we
intend to give them. Slide 9 COL Karl Friedl/MCMR-TT (301-619-7967)
(DSN 343) [email protected] UNCLASSIFIED Slide 9 of 48
Current Priorities: Secretary Gates' Budget Briefing April 6, 2009
Recognize the critical and permanent nature of wounded, ill and
injured, traumatic brain injury, and psychological health programs.
This means institutionalizing and properly funding these efforts in
the base budget and increasing overall spending by $300 million.
The department will spend over $47 billion on healthcare in FY10.
Slide 10 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 10 of 48 Enduring
Challenges: Old Medical Threats, New Science SHELL SHOCK HEMORRHAGE
LIMB LOSS Slide 11 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 11 of 48 Core Medical
R&T Responds to Threats to Soldier Health and Performance
Environmental Hazards Heat and Cold Altitude Toxic Industrial
Chemicals & Materials Systems Hazards Laser Blast Biomechanical
Insults and Stresses Noise Operational Stressors Sleep Deprivation
Traumatic Stress and Situational Stressors Physical Work Load
Cognitive Burden & Operational Complexity Endemic Disease
Threats Parasitic Diseases Bacterial Diseases Viral Diseases
Chemical/Biological Warfare Threats Bacterial Threats Viral Threats
Toxin Threats Nerve Agents Vesicant Agents Blood Agents Combat
Injuries Hemorrhage Head Trauma Blast Injury Inadequate Medical
C4ISR Slide 12 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 12 of 48 Pharmaceutical
Advanced Development Pipeline at USAMMDA Pre-Clinical Phase 1 Phase
2 Phase 3 Licensed VACCINES Adenovirus Type 4 & 7 HIV
Prime-Boost Dengue Tetravalent (Proof-of-Concept) (Proof-of-Concept
Completed) (License Submitted) Leish Drug, Pentostam TM
Antimalarial-IV Artesunate Topical Leishmania Drug
Antimalarial-Tafenoquine Leish Rapid Diagnostic ANTIPARASITIC
DRUGS/Dx (Proof-of-Concept) Intranasal Ketamine RBCs Extended Life
Cryopreserved Platelets Freeze-Dried Plasma COMBAT CASUALTY CARE
Slide 13 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 13 of 48 Military
Infectious Diseases Research Program Vaccines Prophylaxis/treatment
drugs Diagnostics/prognostics Vector control HIV countermeasures
(Congressional mandate) Combat Casualty Care Research Program Meet
Demands on First Responders Reduce the Number of Deaths on the
Battlefield Limit Brain Damage Improve Medic, Provider, and Team
Training Restore Full Function Improve En Route Care Reduce
Morbidity and Died of Wounds Rate Clinical Trials Military
Operational Research Program Prevent, Detect and Treat Mental
Health Problems and mTBI (Concussion) Prevent/Mitigate Blast,
Blunt, Ballistic, and Impact Injury Reduce Attrition in Basic
Combat Training Due to Injury and Mental Health Problems
Prevent/Mitigate Injury from Environmental Exposures to
Heat/Cold/Altitude and Toxic Chemicals and Materials Sustain
Soldier Performance Medical Biological Defense Research Program
Vaccines and pre-treatments Small molecule therapeutics Next
generation diagnostics Animal model development Broad-spectrum
therapeutics Medical Chemical Defense Research Program Nerve agent
pre-treatments Therapeutics for nerve agents Therapeutics for
vesicant injury Diagnostic assays/technologies Clinical and
Regenerative Medicine Research Program Improve Prosthetic Function
Enhance Self Regenerative Capacity Improve Limb/Organ Transplant
Success Create Fully-Functioning Limbs/Organs Blast Injury Program
Coordinating Office Develop Medical Standards for Individual and
Combat Vehicle Crew Blast Protection Systems Elucidate the
Mechanism of Blast-Induced Brain Injury Improve Diagnosis of mTBI
Effectively Communicate Blast-Related Research Across the DoD Reset
Advance Treatment Options OVERARCHING NEEDS: Maintain a Healthy
& Fit Force Protect Personnel in the Field Diagnosis for Early
Treatment Rapid Return to Duty Joint Force Health Protection
Capability Gap Medical R&D Slide 14 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
14 of 48 Key Blast Injury Research Topics (FY07-10 Investments)
Injury Prevention ($183M) Blast Loading CFD Simulation Observed
Pathology FEM Simulation Test ConditionsBlast Loading CFD
Simulation Observed Pathology FEM Simulation Test Conditions
Existence and mechanism of non-impact, blast- induced mTBI? Drugs
to prevent and treat blast-related hearing loss Analysis of combat
injuries and PPE performance (JTAPIC) Multi-effect blast injury
models to improve protective equipment Resilience enhancement and
prevention of PTSD Hair Cell Antioxidan t Defenses Tissue
engineering and prosthetics Return-to-duty Standards Recovery of
function Reset ($141M) Before After Diagnostics and neuroprotectant
drugs for TBI Hemorrhage control & blood products Treatment of
psychological trauma Damage control orthopedics Pain management
Acute Treatment ($437M) Slide 15 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
15 of 48 DoD Blast Injury Research Extends Back to World War II
Cave blasts Armored Med Res Lab Nuclear & conventional
explosions Los Alamos & Albuquerque Slide 16 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 16 of 48 Laying the tracks for the train New
Science and Technology Options: Modernization of Military Medical
R&D Prevention (Mitigate Risk) Acute Treatment (Mitigate
Injury) Reset (Mitigate Disability) Personalized
MedicineDiagnosticsRegenerative Medicine Individual
ResilienceProvider TrainingIndividual Retraining Biomedical
StandardsWound CareAdvanced Prosthetics Injury
SurveillanceOptimized Interventions Return-to-Duty Standards
Systems Biology Methods Advanced Training Technologies &
Neuroplasticity Computational Bioengineering, Biomaterials &
Nanotechnologies Electronic Health Record Outcomes Research Slide
17 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 17 of 48 Chemical
Biological Defense Program Threat Focus Advanced ThreatsAdvanced
Threats pathogens engineered to increase resistance,
transmissibility, and virulence Traditional ThreatsTraditional
Threats intracellular bacterial pathogens (e.g., plague) viral
hemorrhagic fevers (e.g., ebola) Enhanced ThreatsEnhanced Threats
bioprospecting of virulent strains in nature cultivating virulent
strains in the laboratory Emerging ThreatsEmerging Threats natural
diseases (e.g., pandemic flu, malaria) multidrug and vaccine
resistant pathogens Slide 18 COL Karl Friedl/MCMR-TT (301-619-7967)
(DSN 343) [email protected] UNCLASSIFIED Slide 18 of 48
Chemical Biological Defense Program: Transformational Medical
Technologies Initiative Develop broad-spectrum countermeasures and
novel technology platforms (one drug, many bugs) Pursue
countermeasures targeting common disease pathways or enhance the
hosts immune system Integrate best efforts within government,
academia, DoD, biotech industry, and small and large pharmaceutical
corporations Provide seamless end-to-end product development
Eliminate capability gaps by adding promising candidate
technologies to the pipeline www.tmti-cbdefense.org;
ww.fedbizops.gov Slide 19 COL Karl Friedl/MCMR-TT (301-619-7967)
(DSN 343) [email protected] UNCLASSIFIED Slide 19 of 48 The
Changing Operational Environment Low level Persistent Conflict
General Casey, 14 Aug 07 Slide 20 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
20 of 48 The Changing Operational Environment Low level Persistent
Conflict General Casey, 14 Aug 07 Stability Operations &
International Health Stability Operations & International
Health Slide 21 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 21 of 48 Medical
Research and Related Programs in the DoD DCoE for PH and TBI DCoE
for Vision USAMRMC ARO NMRC ONR AFMOA AFRL ONR AFOSR Services DARPA
(e.g., DSO) CBDP/DTRA (e.g., TMTI) SOCOM (BISC) VA-DoD sharing
(e.g., JIF) NIH joint efforts Other Agencies Slide 22 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 22 of 48 Medical Research and Related Programs
in the DoD DCoE for PH and TBI DCoE for Vision USAMRMC ARO NMRC ONR
AFMOA AFRL ONR AFOSR Services DARPA (e.g., DSO) CBDP/DTRA (e.g.,
TMTI) SOCOM (BISC) VA-DoD sharing (e.g., JIF) NIH joint efforts
Other Agencies Slide 23 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN
343) [email protected] UNCLASSIFIED Slide 23 of 48 Armed
Services Biomedical Research Evaluation & Management The ASBREM
Committee shall: Review medical RDT&E program plans and
accomplishments for quality, relevance, and responsiveness to
military operational needs, the needs of the Military Health
System, and the goals of Force Health Protection Review program
plans and budgets in support of the various guidance documents
relevant to National Security and to the missions and functions of
the Department of Defense Provide coordination, recommendations,
and support to DoD Executive Agencies and other DoD officials as
requested, directed, or otherwise appropriate Slide 24 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 24 of 48 Medical Research and Related Programs
in the DoD ASBREM Joint Technical Coordinating Groups 1 Med
Training Systems & Information Tech 2 Military Infectious
Diseases 3 Chemical Defense 4 Biological Defense 5 Military
Operational Medicine 6 Combat Casualty Care 7 Radiation Effects 8
Clinical and Rehabilitative Medicine Slide 25 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 25 of 48 Defense Health Program: GDF Enhancement
MISSION DESCRIPTION AND BUDGET ITEM JUSTIFICATION: This Program
Element (PE) funds Advanced Component Development of medical
products that are regulated by the U.S. Food and Drug
Administration (FDA) and the accelerated transition of FDA licensed
and unregulated products and medical practice guidelines to the
military operational user through clinical and field validation
studies. Projects in this PE are designed to address areas of
interest to the Secretary of Defense and to close medical
capability gaps associated with the Joint Force Health Protection
Concept of Operations (JFHP CONOPS) and are complementary to
research conducted by the Army, Navy and Air Force in analogous
PEs. Projects include Trials for Accelerated Transition of Modeling
and Simulation Technology for Medical Training/Education/Treatment;
Trials for Accelerated Transition of Medical Technology, Practice
Guidelines and Standards; Medical Products Advanced Component
Development; and Medical Information Technology Development. $198 M
Slide 26 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 26 of 48 About 50% of
USAMRMC Funding Each Year Is Congressionally Directed Core Effort
39% Congressional Special Interest (CSI) RDA Programs Function of
Congressional Special Interest (CSI) Research: Sponsor good science
using Congressional appropriations that are not in the Presidents
budgetSponsor good science using Congressional appropriations that
are not in the Presidents budget Responsive to the intent of
Congress, managed to maximize military relevanceResponsive to the
intent of Congress, managed to maximize military relevance Process:
Proposals peer reviewed for scientific merit prior to
awardProposals peer reviewed for scientific merit prior to award
Programs executed by extramural awardees and USAMRMC laboratories
and acquisition officesPrograms executed by extramural awardees and
USAMRMC laboratories and acquisition offices Program Managers:
USAMRMC Research Area Directorates (33%)USAMRMC Research Area
Directorates (33%) U.S. Army Medical Materiel Development Activity
(USAMMDA 9%)U.S. Army Medical Materiel Development Activity
(USAMMDA 9%) Congressionally Directed Medical Research
ProgramsCongressionally Directed Medical Research Programs
Telemedicine and Advanced Technology Research CenterTelemedicine
and Advanced Technology Research Center TATRC 29% CDMRP 32% Core
R&T 33% Advanced Development 9% Slide 27 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 27 of 48 Medical Advanced Development USAMMDA
U.S. Army Medical Materiel Development Activity USAMMA U.S. Army
Medical Materiel Agency Defense Medical Logistics Center
Pharmaceutical Systems Applied Medical Systems Integrated Clinical
Systems Medical Devices Supporting Commands Slide 28 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 28 of 48 Core Medical R&T Supporting
Laboratories Combat Casualty Care 18.3% Military Operational
Medicine 17.1% Military Infectious Diseases 23.6% USAARL U.S. Army
Aeromedical Research Laboratory USAISR U.S. Army Institute of
Surgical Research USARIEM U.S. Army Research Institute of
Environmental Medicine Medical Biological Defense 25.5% Medical
Chemical Defense 15.5% USAMRIID U.S. Army Medical Research
Institute of Infectious Diseases USAMRICD U.S. Army Medical
Research Institute of Chemical Defense WRAIR Walter Reed Army
Institute of Research U.S. Army Medical Research Unit - Nairobi,
Kenya Armed Forces Res Inst of Med Sci, Bangkok, Thailand US Army
Medical Research Unit, Heidelberg, Germany US Army Dental and
Trauma Research Detachment US Army Medical Research Detachment US
Army Center for Env Health Med Slide 29 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
29 of 48 http://cdmrp.army.mil/ FY09 Funding Opportunities: Slide
30 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 30 of 48
http://cdmrp.army.mil/ Slide 31 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
31 of 48 Medical Research and Related Funding Programs in the DoD
DCoE for PH and TBI DCoE for Vision USAMRMC ARO NMRC ONR AFMOA AFRL
ONR AFOSR Services DARPA (e.g., DSO) CBDP/DTRA (e.g., TMTI) SOCOM
(BISC) VA-DoD sharing (e.g., JIF) NIH joint efforts Other Agencies
Small Business Innovative Research Small Business Technology
Transfer (SBIR/STTR) http://www.acq.osd.mil/osbp/sbir/ Slide 32 COL
Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 32 of 48 Robotic rescue
& evacuation Shelf stable diagnostics & vaccines Blood
products & blood safety Natural orifice transluminal endoscopic
surgery Advanced medical imaging Distance medical training &
simulation Operating room of the future Prosthetics and human
performance Regenerative medicine & biomaterials Virtual
environments Computational models & tools Human/soldier phenome
Performance & injury prediction models Cell phone-based systems
Remote biomonitoring Global Biosurveillance Health information
portal unified EHR Research data cube/ medical outcomes
Pharmacovigilance e-HEALTH MEDICINE IN AUSTERE ENVIRONMENTS
DIGITALWARRIOR INTEGRATIVEMEDICINE HOSPITAL OF THE FUTURE Optimal
healing environments Advanced pain management Complementary and
alternative medicine Neuroplasticity/resilience
Genomics/personalized medicine KEY TATRC Initiatives and Portfolios
www.tatrc.org Slide 33 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN
343) [email protected] UNCLASSIFIED Slide 33 of 48 TATRC
Portfolios Resilience & Retraining MAJ Brininger Human
Performance Optimization Dr. Cardin Psych Health Dr. Shore
Simulation & Training Technology Mr. Wiehagen Bio-Monitoring
Technologies Dr. Lai Medical Robotics Dr. Gilbert Advanced
Prosthetics Mr. Turner Genomics / Proteomics Ms. Stanley
International Health Ms. Barrigan Medical Imaging Technologies Dr.
Pacifico Health Information Technologies LCDR Steffensen
Computational Biology Dr. Reifman Nano-Medicine & Biomaterials
Dr. Grundfest Regenerative Medicine Dr. Lai Infectious Disease Dr.
Carney Medical Logistics Mr. DePasquale Blood Products & Safety
Mr. Malloy Trauma Dr. Broderick Vision Mr. Read Acoustic Trauma Dr.
Holtel Head & Spinal Cord Injury Dr. Curley Joint Technical
Coordinating Group 1. Medical Information & Training
Technologies 4. Infectious Diseases 5. Military Operational
Medicine 6. Combat Casualty Care 8. Clinical & Rehabilitative
Medicine Slide 33 of 12 Slide 34 COL Karl Friedl/MCMR-TT
(301-619-7967) (DSN 343) [email protected] UNCLASSIFIED Slide
34 of 48 Hawaii Federal Health Care Network (AKAMAI II) FY10
Competitive RFP AKAMAI II supports applied research, development
and deployment of telehealth and healthcare technology,
biotechnology, clinical informatics, VA/DoD systems
interoperability, to improve access and the quality of care to
service members, their families, and impacted communities. With a
focus on programs that align closely with military medical
requirements, a competitive process will be used to provide funding
in Hawaii to develop advanced medical technologies and
biotechnology research critical to our nation's military medicine
and the warfighter. Priority will be given to innovative
collaborations between Hawaii-based industries and the Department
of Defense. Outside partnerships that help to bring unique
expertise to research in Hawaii to solve military medical problems
will also be an important factor.
http://inouye.senate.gov/Congressional_Initiatives/
http://inouye.senate.gov/Congressional_Initiatives/ Slide 35 COL
Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 35 of 48 Basic Steps to
Innovation in the Hawaii Federal Health Care Network 1.Come up with
a concept that would be immensely important to the DoD, if
successful 2.Secure the intellectual property 3.Publish the seminal
supporting article in peer reviewed literature 4.Conduct the
initial risk mitigation studies (e.g., toxicity) that will
encourage investors Slide 36 COL Karl Friedl/MCMR-TT (301-619-7967)
(DSN 343) [email protected] UNCLASSIFIED Slide 36 of 48
Hawaii Biomedical Research Advantages and Dual Use Applications for
DoD Stable population (~1.2M)Stable population (~1.2M) Unique
healthcare system and DoD-VA sharing of facilities (great starting
point to optimize practices)Unique healthcare system and DoD-VA
sharing of facilities (great starting point to optimize practices)
Distributed across islands (e.g., model of remote health care
access)Distributed across islands (e.g., model of remote health
care access) Chronic health care concerns, even though a state with
the best longevity (e.g., preventive medicine interventions and
personalized health care/personal empowerment opportunities)Chronic
health care concerns, even though a state with the best longevity
(e.g., preventive medicine interventions and personalized health
care/personal empowerment opportunities) Modest size makes
manageable testbed and model system and increases cooperation in
the islandsModest size makes manageable testbed and model system
and increases cooperation in the islands Slide 37 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 37 of 48 AAMTI: Pediatric Telecardiology
Referrals with Echocardiographic Validation Pacific Rim Pediatric
Heartsounds Trial: Store and Forward telcardiology with
echocardiographic validation Simultaneous Multi-site
Phonocardiography: A simplified heartsound Improved heartsound
signal analysis using simultaneous multi-site phonocardiograms in
children Pediatric Multi-site Phonocardiography: Automated
interpretation of pediatric heartsounds Telecardiology evaluation
of newborns with heart murmurs using simultaneous, multi-site
phonocardiography AMEDD ADVANCED MEDICAL TECHNOLOGY INITIATIVE
Slide 38 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 38 of 48 Janus DoD and
VA Common Data View Slide 39 COL Karl Friedl/MCMR-TT (301-619-7967)
(DSN 343) [email protected] UNCLASSIFIED Slide 39 of 48
Pacific Asynchronous Tele-Health (PATH) Teleconsultation Telehealth
Services -VA Pacific Islands Health Care System (VAPICS) Slide 40
COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 40 of 48 Telehealth
Voice Therapy in Remote Regions in the Pacific Basin ICU Multipoint
Military Pacific Consultation Using Telehealth (IMMPACT) Slide 41
COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 41 of 48 Environmental
Medical Surveillance (CBI wet ware / canary) Cell Matrix Chips for
Air/Water Monitoring of Toxic Chemicals Principal Investigator:
Kevin Chinn, PhD; Cellular Bioengineering, Inc. Slide 42 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 42 of 48 Cell-based Treatments Development of
Technologies for Bioengineered Tissue Repair Principal
Investigator: Mark Mugiishi, MD; Cellular Bioengineering, Inc.
Treatment of Peripheral Vascular Disease by Adipose Derived Stromal
Cell Injection Principal Investigator: Paul Kosnik PhD; Tissue
Genesis, INC. Slide 43 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN
343) [email protected] UNCLASSIFIED Slide 43 of 48
Nanotechnology Capabilities RAIDER: Rapid Adverse Identifier for
Drugs and Evaluation Resource Principal Investigator: Joanne S.M.
Ebesu, Ph.D.; Oceanit SEM image of nanoarray functionalized with
antibodies Slide 44 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN
343) [email protected] UNCLASSIFIED Slide 44 of 48
Development of the versaHSDI system Colon Automated disease
detection Automated disease detection Video reconstructed colon
model Video reconstructed colon model Local 3D rendering Local 3D
rendering 3-D rendering software development to enable and develop
Computer Aided Diagnosis and in situ pathology for colon cancer
detection Slide 45 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 45 of 48
Neurophysiologically-based Performance Monitoring and Enhancement
Devices Intelligent PTSD Classification and Treatment-Augmentation
Technology The device will utilize off the shelf technology and
Archinoetics developed hardware to produce an integrated,
unobtrusive monitoring/communication capability. Warfighter
Physiologic System Interface Research Slide 46 COL Karl
Friedl/MCMR-TT (301-619-7967) (DSN 343) [email protected]
UNCLASSIFIED Slide 46 of 48 Broadband Respiratory Virus
Surveillance Slide 47 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN
343) [email protected] UNCLASSIFIED Slide 47 of 48 SimCenter
Hawaii Technology Enabled Learning and Intervention Systems Virtual
Reality Applications for Health Care Education and Training Slide
48 COL Karl Friedl/MCMR-TT (301-619-7967) (DSN 343)
[email protected] UNCLASSIFIED Slide 48 of 48 TATRC Science
& Engineering Research Support Dr. Stan Saiki, Chief, TATRC Hui
Dr. Chuck Peterson, Chief Scientist Ms. Jessica Kenyon, Chief,
TATRC West Mr. Ron Marchessault, ORTA www.tatrc.org
